- This event has passed.
ONLINE: Mike Zamiara, Niowave, Inc.
June 4, 2021 @ 7:30 am - 8:30 am
President and CFO
Click here to register: https://tennessee.zoom.us/meeting/register/tJYpcuGrqT4pE9xpcT0s7L2VWoRhYEPNN_R2
Mike Zamiara is the president and CFO of Niowave, Inc. Niowave manufactures and operates superconducting electron linear accelerators to produce medical isotopes. Niowave has multiple licenses with the NRC to work with both uranium and radium and is scaling up their process to produce molybdenum-99 under the NNSA’s Mo-99 Co-op Program. Niowave is also scaling up their process to produce actinium-225 (Ac-225) from radium. Ac-225 is used for cancer therapy.
Mr. Zamiara has over 30 years of experience in various roles in regulated industries. This includes extensive experience with the FDA. He is a results-oriented, senior executive with extensive healthcare industry experience, including biotechnology and medical device manufacturing. He has been a senior executive in charge of M&A, working closely with investment banks to develop transaction structure, and successfully closing multiple transactions. He successfully led the post-purchase integration for multiple acquisitions and is committed to fostering a culture that is open and collaborative.
Mr. Zamiara began his career as a CPA with Plante & Moran in 1987 and became a partner in the manufacturing practice in 1998. He left Plante in 2000 to serve as Chief Financial Officer and Chief Operating Officer for Emergent BioSolutions (the world’s only FDA-licensed anthrax vaccine manufacturer). After successfully positioning Emergent for an Initial Public Offering (IPO), he became the CEO of Orchid Orthopedics, a medical device contract manufacturer with ten locations throughout the US. He agreed to join Niowave in 2015 to bring his experience helping middle market companies grow strategically through acquisition and through commercialization of existing product portfolios.
Mr. Zamiara is also the chair-elect of the Greater Lansing Area Chamber of Commerce and the co-Chair of the Lansing Economic Area Partnership’s MedTech Initiative
Niowave is a domestic supplier of medical and industrial radioisotopes from uranium and radium. Isotope inventories available for purchase include alpha, beta, and gamma sources. The system uses a superconducting linac instead of a nuclear reactor which is simpler to operate and less costly to license. It also eliminates the need for a nuclear reactor and weapons grade uranium (HEU). The small batch radiochemistry operations can be automated, and do not require licensing as a nuclear reprocessing facility. Isotope production and distribution utilize existing radiopharmaceutical supply chain and FDA approval processes.